Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Determining the role of Reactive Oxygen Species (ROS) and Superoxide dismutase 1 (Sod1) in lung cancer and melanoma development
FY 2022-23
Summary
Lung cancer is the deadliest cancer, responsible for more deaths than breast, prostate, and colorectal cancers combined. Despite available treatments, the 5-year survival rate has stagnated for the past 20 years, bottoming out at less than 20%.
When cells divide, they reach a critical checkpoint at which they must meet certain requirements before going forward with proliferation. Lung cancer cells abnormally bypass this checkpoint due largely to mutations in KRAS and BRAF, two protein sentinels standing guard at the checkpoint. As they divide, lung cancer cells undergo normal cellular processes at a faster rate, and therefore accrue waste products more quickly. Some of these waste products are Reactive Oxygen Species (ROS), which spontaneously damage internal cellular structures including DNA, lipids, and proteins. In normal cells, ROS are combatted by an enzyme called Superoxide Dismutase 1 (Sod1), which is capable of neutralizing destructive ROS. Because cancer cells augment ROS production, it is thought that they may also upregulate Sod1 to preserve the balance of damage mitigation. Preliminary results show that Sod1 plays a key role in maintaining the health of cancer cells, yet the possibility of cancer management via Sod1 depletion remains uninvestigated.
Using Genetically Engineered Mouse Models (GEMMs), I am able to model tumor induction via KRAS or BRAF mutation, paired with concurrent removal of Sod1. I can then follow tumor development until predetermined endpoints, at which point ROS level, DNA, lipid, and protein damage, and tumor severity can be measured. These GEMMs allow for targeted and controlled investigation, with the goal of developing new therapies and improving the 5-year survival for those diagnosed with lung cancer.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
486141
Name
Papp Timea
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Determining the role of Reactive Oxygen Species (ROS) and Superoxide dismutase 1 (Sod1) in lung cancer and melanoma development
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antioxidants; Genetically Engineered Mouse Models; Lung Cancer; Melanoma; Oxidative Damage; Reactive Oxygen Species (Ros); Tumorigenesis And Development
Abstract
Lung cancer is the deadliest cancer, responsible for more deaths than breast, prostate, and colorectal cancers combined. Despite available treatments, the 5-year survival rate has stagnated for the past 20 years, bottoming out at less than 20%.
When cells divide, they reach a critical checkpoint at which they must meet certain requirements before going forward with proliferation. Lung cancer cells abnormally bypass this checkpoint due largely to mutations in KRAS and BRAF, two protein sentinels standing guard at the checkpoint. As they divide, lung cancer cells undergo normal cellular processes at a faster rate, and therefore accrue waste products more quickly. Some of these waste products are Reactive Oxygen Species (ROS), which spontaneously damage internal cellular structures including DNA, lipids, and proteins. In normal cells, ROS are combatted by an enzyme called Superoxide Dismutase 1 (Sod1), which is capable of neutralizing destructive ROS. Because cancer cells augment ROS production, it is thought that they may also upregulate Sod1 to preserve the balance of damage mitigation. Preliminary results show that Sod1 plays a key role in maintaining the health of cancer cells, yet the possibility of cancer management via Sod1 depletion remains uninvestigated.
Using Genetically Engineered Mouse Models (GEMMs), I am able to model tumor induction via KRAS or BRAF mutation, paired with concurrent removal of Sod1. I can then follow tumor development until predetermined endpoints, at which point ROS level, DNA, lipid, and protein damage, and tumor severity can be measured. These GEMMs allow for targeted and controlled investigation, with the goal of developing new therapies and improving the 5-year survival for those diagnosed with lung cancer.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Papp, Timea
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~